ESTRO Brachytherapy for Prostate Cancer 2018

CONCLUSION: A predictive model for a postimplant nomogram for prostate cancer recurrence at 9-years after PPB has been developed and validated from a large multi-institutional database.

This study also demonstrates the significance of implant dosimetry for predicting outcome.

International Journal of Radiation Oncology, Biology, Physics, 2010, Vol.76(4), pp.1061-1065